+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Platelet von Willebrand's antigen II: active release by aggregating agents and a marker of platelet release reaction in vivo

Platelet von Willebrand's antigen II: active release by aggregating agents and a marker of platelet release reaction in vivo

Blood 58(6): 1075-1080

von Willebrand's antigen II (vW AgII), a plasma and platelet antigen immunologically and biochemically distinct from factor-VIII-related antigen (VIIIR:Ag), is decreased in von Willebrand's disease. vW AgII is released from platelets during aggregation and clotting. The release of platelet vW AgII was studied in washed platelets following aggregation by thrombin, collagen, and adenosine diphosphate (ADP). Total platelet vW AgII was 3.39 U/10(9) platelets. Thrombin and collagen yielded release of 85% and 86% of platelet vW AgII, respectively, at the highest concentrations. Release of platelet vW AgII was correlated with the release of 5-hydroxytryptamine (5HT). Release of vW AgII by collagen and thrombin was inhibited by metabolic inhibitors. In addition, collagen release of vW AgII was inhibited by aspirin. In clinical syndromes associated with intravascular platelet destruction, marked elevations of plasma vW AgII were noted. Thus, vW AgII is released by a metabolically active process from platelets during aggregation. In addition, vW AgII appears to be a marker of intravascular platelet destruction.

(PDF emailed within 1 workday: $29.90)

Accession: 006135247

Download citation: RISBibTeXText

PMID: 6975640

Related references

Ultrastructure of the platelet release reaction in response to various aggregating agents and their inhibitors. Laboratory Investigation; A Journal of Technical Methods and Pathology 29(6): 595-606, 1973

Release of platelet factor 4 by adenosine diphosphate and other platelet-aggregating agents. British Medical Journal 1(5594): 746-747, 1968

Release of platelet factor 4 by adp and other platelet aggregating agents human. British Medical Journal (5594): 746-747, 1968

In vivo platelet alpha granule release comparison of plasma levels of beta thrombo globulin platelet factor 4 and thrombospondin as markers of the release reaction. Thrombosis & Haemostasis: 123, 1983

In vitro and in vivo studies on a new platelet release protein von willebrand antigen ii. Clinical Research 28(2): 323A, 1980

beta-Thromboglobulin--a specific marker of in-vivo platelet release reaction. Thrombosis and Haemostasis 44(1): 23-29, 1980

Phosphorylation of human platelet proteins caused by agents that induce or inhibit the platelet release reaction. Federation Proceedings 37(3): 799, 1978

Further evidence for the role of thrombin in the platelet release reaction caused by various agents and the nature of biphasic platelet aggregation. British Journal of Haematology 38(3): 381-390, 1978

Plasma beta-thromboglobulin level in thromboembolic diseases: a marker of in-vivo platelet release reaction. Giornale di Clinica Medica 61(9): 672-678, 1980

The effect of inhibition of the platelet release reaction on platelet behaviour in vitro and in vivo. Scandinavian Journal of Haematology 9(4): 322-332, 1972

Preservation of platelet receptors for platelet aggregating factor/von Willebrand factor by air drying, freezing, or lyophilization: new stable platelet preparations for von Willebrand factor assays. Thrombosis Research 13(4): 591-597, 1978

Effects of platelet aggregating agents and anti platelet aggregating agents on prostacyclin prostaglandin i 2 generation. Journal of Kyoto Prefectural University of Medicine 90(2): 125-138, 1981

Enhanced in vivo platelet release reaction increased thromboxane synthesis and decreased prostacyclin release after tourniquet ischemia. Lancet 2(8196): 663-667, 1980